MiniMed Flex Launch Drives Strong Q1, Raised Outlook
MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.
The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.
Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.
The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.
Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.
The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.
Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.
This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.